EMA

May 2019

Centralized Monitoring: a Greater Advantage to a Broader Range of Trials

By |2019-07-19T14:05:06+00:00May 2, 2019|Blog, Infographic|0 Comments

Regulatory bodies are unanimous, today's clinical research needs Centralized Monitoring. We summarized Centralized Monitoring the infographic way, download your free copy here...

Apr 2019

FDA Q&A Draft Guidance Document: The RBM Process-Technology Fit

By |2019-05-27T15:16:11+00:00April 15, 2019|Blog|0 Comments

Our expert team reviewed the March 2019 RBM Q&A draft guidance document and extended the FDA guidance with RBM solution specific insights and a MindMap to help you even further.

Feb 2019

3 Critical Aspects of Clinical Trial Conduct that Affect the Totality of Evidence

By |2019-02-27T20:13:40+00:00February 27, 2019|Blog|0 Comments

Even without it being mandated, health authorities typically expect pharma and biotech companies to conduct two well-controlled Phase 3 trials demonstrating efficacy and safety. Still today this principle ensues discussions regarding the quantity and quality of the evidence needed to establish effectiveness.

Jan 2019

Quality Tolerance Limits versus Key Risk Indicators, The Difference

By |2019-07-19T14:01:39+00:00January 18, 2019|Blog, Infographic|0 Comments

To clear up confusion surrounding the interpretation and use of QTLs and KRIs, we have created an easy to understand infographic for all clinical research experts involved in quality control.

Dec 2014

Duality of Risk-based Monitoring Definition: EMA vs FDA

By |2019-03-21T12:16:18+00:00December 9, 2014|White Paper|Comments Off on Duality of Risk-based Monitoring Definition: EMA vs FDA

In October 2014 at the Risk-based Monitoring conference in Copenhagen the Senior Director QA Operations of Janssen, Jan Van Parijs said: "Industry is historically heavily regulated, so as an industry we are kind of used to the fact that the authorities provide a set [...]

Upcoming Events

Register Today!

Get Free Test Access